Puerto Rico's 4% tax hikes on foreign companies slammed by PhRMA and BIO

29 October 2010

As part a new legislation that was signed this week by the government of Puerto Rico, Law 154, it is proposed to levy a 4% tax on foreign corporations. Puerto Rico’s Governor Luis Fortuno unveiled the fiscal package as part of an economic development and budget-deficit reduction plan for the commonwealth.

The plan will provide tax relief for the current 2010 tax year, and starting January 1, 2011, would reduce individual tax rates by 50% and 30% for businesses, providing an average of $1.2 billion in annual tax relief during the next six years, according to the Puerto Rico Federal Affairs Administration (PRFAA).

According to a Reuters report, the tax would target between 40 and 50 firms operating in Puerto Rico that make more than $75 million annually. The measure is scheduled to take effect January 1, 2011 and run through 2016 with a tax levy of 4% in 2011, 3.75% in 201, and 2.75% in 2013, according Reuters.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology